Use of Fertility Drugs and Risk of Ovarian Cancer: Results from a U.S.-Based Case-Control Study
Use of Fertility Drugs and Risk of Ovarian Cancer: Results from a U.S.-Based Case-Control Study
复制标题
DOI：
10.1158/1055-9965.epi-12-0426
复制
发表时间：
2012-08-01
影响因子：
3.8
通讯作者：
Diergaarde, Brenda
中科院分区：
文献类型：
--
作者：
Kurta, Michelle L.;Moysich, Kirsten B.;Diergaarde, Brenda
背景：先前研究检查生育药物的使用与卵巢癌风险之间的关系，得出了相互矛盾的结果。我们使用了一个大型病例对照研究的数据，以确定生育药物的使用是否显着影响卵巢癌的风险时，考虑到产次，妊娠，和原因infertiles.Methods：数据来自激素和卵巢癌预测（HOPE）研究（902例，1,802对照）。通过面对面访谈收集病史和生育史。采用Logistic回归计算OR和95%置信区间（CI）。模型调整了年龄，种族，教育，初潮年龄，产次，口服避孕药的使用，母乳喂养，滑石粉的使用，输卵管结扎，乳腺癌/卵巢癌的家族史。（OR，0.93; 95% CI，0.65-1.35）或报告因不孕症寻求医疗照顾的妇女（OR，0.87; 95% CI，0.54-1.40）。我们确实观察到，在那些尽管因怀孕问题寻求医疗照顾但仍未怀孕的妇女中，结论：本研究结果进一步证明，在大多数妇女中，使用助孕药与卵巢癌的发生风险无显著相关性;然而，尽管不孕症评估和生育药物的使用仍然未孕的妇女，可能有卵巢cancer.Impact的风险升高：我们的研究结果表明，生育药物的使用并不显着有助于卵巢癌的整体风险时，调整已知的混杂因素。癌症流行病学生物标志物Prev; 21（8）; 1282-92。(c)2012年AACR。
Background: Previous studies examining associations between use of fertility drugs and ovarian cancer risk have provided conflicting results. We used data from a large case control study to determine whether fertility drug use significantly impacts ovarian cancer risk when taking into account parity, gravidity, and cause of infertility.Methods: Data from the Hormones and Ovarian Cancer Prediction (HOPE) study were used (902 cases, 1,802 controls). Medical and reproductive histories were collected via in-person interviews. Logistic regression was used to calculate ORs and 95% confidence intervals (CI). Models were adjusted for age, race, education, age at menarche, parity, oral contraceptive use, breastfeeding, talc use, tubal ligation, and family history of breast/ovarian cancer.Results: Ever use of fertility drugs was not significantly associated with ovarian cancer within the total HOPE population (OR, 0.93; 95% CI, 0.65-1.35) or among women who reported seeking medical attention for infertility (OR, 0.87; 95% CI, 0.54-1.40). We did observe a statistically significant increased risk of ovarian cancer for ever use of fertility drugs among women who, despite seeking medical attention for problems getting pregnant, remained nulligravid (OR, 3.13; 95% CI, 1.01-9.67).Conclusions: These results provide further evidence that fertility drug use does not significantly contribute to ovarian cancer risk among the majority of women; however, women who despite infertility evaluation and fertility drug use remain nulligravid, may have an elevated risk for ovarian cancer.Impact: Our results suggest that fertility drug use does not significantly contribute to overall risk of ovarian cancer when adjusting for known confounding factors. Cancer Epidemiol Biomarkers Prev; 21(8); 1282-92. (c) 2012 AACR.